MGTX · MeiraGTx Holdings
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $10.91
Note written ·
Price against the kill line
15.9% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $10.91, on record since 11 November 2026. The shares are down 33.3% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $10.91, over the 50-day average of closes, which would show the shares leading the S&P 500. A US bota-vec filing announced before the first quarter of 2027 would also show the case failing.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 4.8
- Revenue, change on a year (%)
- +1074.1
- Operating margin (%)
- −1036.1
- Free cash flow, four quarters ($M)
- −3.0
- Net cash, cash less debt ($M)
- 62.8
- Price to earnings (×)
- 11.5
- Enterprise value to sales (×)
- 2.1
- Enterprise value to operating income (×)
- 4.6
All filed numbers
What MeiraGTx Holdings reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 4.8 | +1074.1 | −1036.1 |
| first filed | 321 | +8608.6 | 76.0 |
| first filed | 0.3 | −84.8 | −13930.7 |
| first filed | 75.4 | +252.3 | 35.1 |
| first filed | 0.4 | −96.2 | −11232.0 |
| first filed | 3.7 | +1208.9 | −1213.6 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: 78.3 | −51.2 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +19.7 |
| Operating cash flow ($M) | 1.4 |
| Capital spending ($M) | 4.3 |
| Free cash flow ($M) | −3.0 |
| Cash and short-term investments ($M) | 185 |
| Debt ($M) notes | 122 |
| Net cash, cash less debt ($M) | 62.8 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) at 31 March 2026, filed 14 May 2026 | 3.3 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) including non-controlling interests | 215 |
| Market value ($M) | 897 |
| Enterprise value, market value plus net debt ($M) | 834 |
| Enterprise value to sales (×) | 2.1 |
| Enterprise value to operating income (×) | 4.6 |
| Price to earnings (×) | 11.5 |
| Price to book value (×) | 4.2 |
| Free-cash-flow yield (%) | −0.3 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 6.6% of shares outstanding sold short, 6.5 days of average trading to cover, +7.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $1.7M |
| 12 monthsfrom | $0 | $4.7M |
The thesis
MeiraGTx's shares are more likely to lag the S&P 500 over the next three months. The company's third-quarter report of 12 November 2026 moved the US Biologics License Application (BLA) for bota-vec, its gene therapy for X-linked retinitis pigmentosa (XLRP), to the first quarter of 2027. Its second-quarter release of 13 August 2026 had guided regulatory submissions for 2026. The European submission in December 2026 and the US filing itself settle the case.
The shares closed at $8.79 on 12 November 2026, down from $9.68 on 11 November 2026, per adjusted daily closes. That is 42.7% below the 52-week intraday high of $15.35 set on 7 July 2026, and the three-month change is −35.0%. The 50-day average of closes is $10.81 and the 200-day average is $10.37, both above the last close.
Beacon Therapeutics reported on 21 September 2026 that its XLRP therapy laru-zova met the primary endpoint of its pivotal VISTA trial. Bota-vec's LUMEOS trial missed its endpoint under Johnson & Johnson before MeiraGTx reacquired the rights in May 2026. The third-quarter release does not mention any FDA feedback on whether the agency will review bota-vec on the existing data.
Bullish and bearish views on MeiraGTx Holdings plc
The bull case on MeiraGTx Holdings plc (MGTX), in brief: cash runs into the second half of 2028. The bear case: the US filing slipped.
Bull case
- Cash runs into the second half of 2028. The 12 November 2026 release reported $186.8 million of cash, cash equivalents and restricted cash at 30 September 2026, against $145.4 million at 30 June 2026. Management said that runway includes a $95.0 million upfront payment due from Hologen and excludes about $135.0 million of potential near-term milestone cash from Eli Lilly and any further Oberland tranches.
- The European dossier is finished. The release said the marketing authorisation application to the European Medicines Agency is "complete and in publishing", with submission intended for December 2026, subject to EMA confirmation of the date. Process performance qualification is complete. Bota-vec holds FDA Fast Track and orphan designations, and PRIME status in the EU.
- A second programme has a partner. Lilly holds worldwide exclusive rights to AAV-AIPL1; MeiraGTx received a $75 million upfront payment and is eligible for more than $400 million in milestones plus tiered royalties, per the 12 November 2026 release.
- The AQUAx2 readout is dated. The 12-month pivotal data for AAV2-hAQP1 in radiation-induced dry mouth are expected in mid-2027, and a positive result could support a BLA by the end of 2027, per the same release.
Bear case
- The US filing slipped. The 12 November 2026 release moved the full bota-vec BLA to the first quarter of 2027 and the first commercial launch to late 2027. The second-quarter release had guided global submissions for 2026.
- The rival has a positive pivotal trial. Beacon reported on 21 September 2026 that 31.0% of high-dose patients met the responder definition (p=0.0019) and 24.1% of low-dose patients did (p=0.0106). Beacon planned to start a rolling BLA later in 2026, which would narrow bota-vec's timing lead.
- The quarter missed estimates. Benzinga reported on 12 November 2026 that third-quarter loss per share of $0.53 was wider than the $0.50 estimate, and revenue of $4.814 million was below the $6.953 million estimate. Research and development expense was $39.316 million, against $32.532 million a year earlier.
- Executives keep selling. SEC Form 4 filings show CFO and COO Richard Giroux sold 56,000 shares at $9.95 on 20 October 2026, and Chief Scientific Officer Stuart Naylor sold 27,659 shares at $10.64 on 6 October 2026. Both sales ran under Rule 10b5-1 plans, which are pre-arranged. Chief executive Alexandria Forbes sold 62,000 shares at $13.86 on 18 August 2026, also under a plan.
- Further Oberland money is conditional. The Oberland royalty notes are senior secured, with a first claim on sales of AAV2-hAQP1, bota-vec and AAV-AIPL1. Each later tranche depends on regulatory or data milestones, so a slower regulatory path holds back that capital.
Price setup
The shares closed at $8.79 on 12 November 2026 after closing at $9.68 on 11 November 2026 and $8.51 on 5 November 2026. The 52-week closing low is $6.99, set on 5 March 2026. The 52-week intraday high is $15.35, set on 7 July 2026, and the close on 14 August 2026 was $13.52.
The shares sit below both the 50-day average of $10.81 and the 200-day average of $10.37, per adjusted daily closes. A recovery of the 50-day average would put the shares above the level their recent decline has been measured against; the 9 November to 11 November 2026 closes of $9.49, $9.62 and $9.68 did not reach it.
Selling pressure comes from three dated sources: the Form 4 sales of 18 August 2026, 6 October 2026 and 20 October 2026, the rival data of 21 September 2026 and the slipped US filing date of 12 November 2026.
Catalysts ahead
- ~31 December 2026 (est.): Submission of the bota-vec marketing authorisation application to the European Medicines Agency, which the company intends for December 2026 subject to EMA confirmation. It is the first regulatory filing for bota-vec and shows whether the delayed US timetable is the only slip.
- ~31 March 2027 (est.): Full bota-vec BLA submission to the FDA, guided for the first quarter of 2027. It shows whether the FDA will review bota-vec after a missed Phase 3 endpoint and whether the new date holds.
- ~30 June 2027 (est.): AQUAx2 12-month pivotal data readout for AAV2-hAQP1 in radiation-induced dry mouth, guided for mid-2027. It is the clinical result for the second programme and the trigger for a $50 million Oberland data tranche.
What would change the view
A daily close above $10.91, over the 50-day average of closes, which would show the shares leading the S&P 500. A US bota-vec filing announced before the first quarter of 2027 would also show the case failing.
What it trades with
MGTX trades on company-specific regulatory news. The closest read-across is Beacon Therapeutics' laru-zova programme in the same disease, and the start of Beacon's rolling BLA would be the next direct comparison. Revenue is mostly related-party and lumpy, so quarterly sales move the shares less than regulatory timing and financing terms do.
The evidence, claim by claim (8)
- Cash, cash equivalents and restricted cash were $186.8 million at 30 September 2026; management guided runway into the second half of 2028. MeiraGTx third-quarter 2026 results release (8-K exhibit 99.1) · as of
- The full bota-vec BLA is expected in the first quarter of 2027, the European marketing authorisation application in December 2026, and first commercial launch in late 2027. MeiraGTx third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Third-quarter 2026 revenue was $4.814 million; net loss attributable to shareholders was $51.212 million, or $0.53 per share; research and development expense was $39.316 million. MeiraGTx third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Loss per share of $0.53 compared with an estimate of $0.50, and revenue of $4.814 million with an estimate of $6.953 million. Benzinga headline, 12 November 2026 · as of
- Beacon Therapeutics reported that laru-zova met the primary endpoint of its pivotal VISTA trial in XLRP, with a 31.0% responder rate at high dose (p=0.0019) and 24.1% at low dose (p=0.0106). Beacon Therapeutics press release via GlobeNewswire · as of
- CFO and COO Richard Giroux sold 56,000 shares at $9.95 under a Rule 10b5-1 plan. SEC Form 4 filed 20 October 2026 · as of
- Chief Scientific Officer Stuart Naylor sold 27,659 shares at $10.64 under a Rule 10b5-1 plan. SEC Form 4 filed 6 October 2026 · as of
- Lilly holds worldwide exclusive rights to AAV-AIPL1; MeiraGTx received $75 million upfront and is eligible for over $400 million in milestones plus tiered royalties. MeiraGTx third-quarter 2026 results release (8-K exhibit 99.1) · as of
Sources
- MeiraGTx Holdings plc - Form 8-K - FY2026 · sec.gov
- MeiraGTx Reports Second Quarter 2026 Financial and Operational Results · investors.meiragtx.com
Related · shared themes
TVTX
Travere Therapeutics
Travere Therapeutics' FILSPARI kidney-drug sales beat the third-quarter benchmark at $200.2 million, but new patient start forms slipped to…
ABEO
Abeona Therapeutics
Abeona Therapeutics' ZEVASKYN revenue grew 18% to $13.5 million in the third quarter but missed estimates, and a $3.75-a-share placement…
ARCT
Arcturus Therapeutics Holdings
Arcturus Therapeutics has cash into 2028 but no dated FDA path for ARCT-810 and no dated Phase 3 decision for ARCT-032, so the shares are…
DSGN
Design Therapeutics
Design Therapeutics' shares are more likely to lag the S&P 500: a new $200 million stock-sale program adds supply while DT-216P2's…
See also · stocks to watch